SCHEMBL16259713

SCHEMBL16259713

Cc1c(C(C)(C)C)cc(OBO)cc1C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.41
▸ CA1 P00915 2/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ POLB P06746 1/20 0.40
▸ TYR P14679 1/20 0.40
▸ ALOX15 P16050 3/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ATP2A2 P16615 1/20 0.34
▸ ATP2A3 Q93084 1/20 0.34
▸ HSPA5 P11021 1/20 0.33
▸ CYP2C9 P11712 3/20 0.32
▸ CYP2C19 P33261 3/20 0.32
▸ HIF1A Q16665 2/20 0.32
▸ HPN P05981 1/20 0.32
▸ SIRT5 Q9NXA8 1/20 0.32
▸ ESRRA P11474 2/20 0.31
▸ TP53 P04637 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17298431 0.83 CA2 (0.61) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL17191780 0.74 GABRA1 (0.46) CA2CA1ALDH1A1POLBTYR
SCHEMBL10030214 0.73 TUBB1 (0.32) LMNACYP3A4HPGD
SCHEMBL18715652 0.73 CA2 (0.64) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL17298432 0.72 CA1 (0.33) CA2CA1ALDH1A1
SCHEMBL7047479 0.71 ALDH1A1 (0.62) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL27267523 0.71 CA2 (0.41) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL29163626 0.71 CA2 (0.41) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL12930400 0.70 ALDH1A1 (0.41) CA2SMN1; SMN2ALDH1A1POLBTYR
SCHEMBL25818655 0.70 ALDH1A1 (0.36) CA2CA1ALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815851-B2 Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases PHENEX PHARMACEUTICALS AG (DE) 2017-11-14 — — US disclosed
US-20140349987-A1 PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES PHENEX PHARMACEUTICALS AG (DE) 2014-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349987-A1 PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES RORA, RORB, RORC CA2 1766/4885CA1 1477/4885SMN1; SMN2 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback